Indacaterol/glycopyrronium superior to salmeterol/fluticasone in reducing annual COPD exacerbations: The FLAME Study
1. Indacaterol/glycopyrronium significantly reduced annual COPD exacerbation rates as compared to standard therapy with salmeterol/fluticasone. 2. The adverse events ...




![Combo angiotensin-neprilysin inhibitor superior to enalapril in heart failure [PARADIGM-HF trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/Angiotensin-350x250.jpg)